Fubotv earnings beat by $0.10, revenue topped estimates
IRVING, Texas - Caris Life Sciences (NASDAQ:CAI), an $8.4 billion market cap diagnostics company with a 46.7% gross profit margin, has published a study in Communications Medicine demonstrating that its AI-based image analysis model may more accurately predict cancer biomarkers and patient survival than conventional diagnostic methods. InvestingPro data shows the company maintains a Fair financial health score, suggesting stable operational performance.
The study, which analyzed data from over 35,000 patients, showed the AI model could assess PD-L1 positive phenotype status in breast cancer using only hematoxylin and eosin (H&E) images. Patients identified as positive by the AI model and treated with pembrolizumab achieved a hazard ratio for overall survival of 0.511, compared to 0.882 for traditionally scored PD-L1 immunohistochemistry tests.
This result is consistent with almost doubled survival rates for patients treated with pembrolizumab when selected using the AI method. In colorectal cancer cases, the AI predicted mismatch repair deficiency and microsatellite instability at levels equivalent to traditional scoring methods.
"Traditional PD-L1 testing can undercall positive cases, especially near the 1% threshold," said Matthew Oberley, SVP and Chief Clinical Officer at Caris. "Caris’ AI model enhances predictive accuracy, integrating features from both staining methods."
George W. Sledge, Jr., Caris EVP and Chief Medical Officer, noted that the AI technology could potentially guide immunotherapy decisions and improve patient outcomes.
The research highlights how artificial intelligence might improve the precision of cancer biomarker assessment, which is critical for determining appropriate treatment options. The study suggests that AI-based approaches could complement or potentially replace certain conventional diagnostic methods in oncology. With $452.5 million in trailing twelve-month revenue and strong analyst consensus ratings, InvestingPro subscribers can access detailed financial metrics and 12 additional ProTips about Caris’s growth potential.
The findings were published in Communications Medicine, a Nature portfolio journal, according to the company’s press release statement. Investors should note that Caris will report its next earnings in 6 days, on August 12, 2025, which could provide further insights into the commercial impact of these technological advances.
In other recent news, Caris Life Sciences has published data in the New England Journal of Medicine validating findings on tumor-infiltrating clonal hematopoiesis (TI-CH). The study analyzed 3,255 matched tumor-blood samples, revealing that TI-CH is prevalent across solid tumors, with the highest incidence in non-small cell lung cancer affecting about 23% of patients. Wolfe Research initiated coverage on Caris Life Sciences with an Outperform rating and a price target of $32.00, citing expected revenue growth with compound annual growth rates of 13% in volume and 17% in average selling price from 2024 to 2029. Evercore ISI also began coverage with an Outperform rating and a $33.00 price target, projecting a 40% compound annual growth rate over the next three years. Citi initiated coverage with a Buy rating and a $34.00 price target, highlighting Caris Life Sciences’ unique financial profile and the $412 million in sales generated for fiscal year 2024. TD Cowen followed suit with a Buy rating and a $32.00 price target, noting the potential for a 21% upside. These developments reflect growing analyst confidence in Caris Life Sciences’ growth prospects and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.